---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-142023"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:21:48.710007+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics reports Q1 2023 net loss of $13.3M; provides pipeline updates for SPR720, tebipenem HBr, and SPR206

## Summary
- Net loss of $13.3M ($0.25 per share) in Q1 2023, compared to net loss of $32.8M ($1.01 per share) in Q1 2022.
- Cash and cash equivalents of $96.3M as of March 31, 2023; company expects sufficient funding beyond 2024.
- SPR720 Phase 2 trial in NTM-PD on track for top line data readout in first half of 2024.
- Tebipenem HBr: SPA agreement update expected mid-2023; Phase 3 cUTI trial initiation expected in 2H 2023.
- SPR206: IND submission for Phase 2 trial in hospital-acquired/ventilator-associated bacterial pneumonia expected Q4 2023.

## SEC filing metadata
- accession: 0001193125-23-142023
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/0001193125-23-142023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/d438048d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-142023
- JSON: https://secwatch.observer/filing/0001193125-23-142023.json
- Plain text: https://secwatch.observer/filing/0001193125-23-142023.txt

## Key facts
- Earnings Releases
  Spero Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/0001193125-23-142023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.